People with systemic lupus erythematosus often face a difficult choice between two powerful medicines. This large review looked at data from many trials to see how belimumab and anifrolumab stack up against each other. It involved over 4,300 patients treated for lupus or kidney inflammation caused by the disease.
For general disease control, belimumab showed stronger results. It helped more patients reach a state of remission compared to anifrolumab. However, anifrolumab offered a different advantage. It helped doctors lower the amount of steroid medication patients needed to take. It also helped normalize blood markers that track immune system activity.
Safety remains a key concern. Patients taking anifrolumab had higher rates of shingles compared to those on belimumab. Both drugs carry similar risks for serious infections and death. The comparison for kidney disease outcomes was not clear because the data had wide ranges of uncertainty. This means doctors must weigh the specific benefits and risks for each individual patient.